Research programme: Streptococcal infections therapeutics - Gangagen
Latest Information Update: 28 Sep 2023
At a glance
- Originator GangaGen
- Class Antibacterials; Recombinant proteins
- Mechanism of Action Cell wall modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Streptococcal infections
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for research development in Streptococcal-infections in USA
- 13 Aug 2019 Early research in Streptococcal infections in USA (unspecified route) before August 2019 (Gangagen pipeline, August 2019)